T he risks of cardiovascular diseases (CVD) and all-cause mortality in patients with diabetes mellitus (DM) are thought to be related to suboptimal blood pressure (BP) control over a period of time, but the achieved target for pharmacological BP lowering remains unclear. As one of the key goals of DM management is to minimize the risk of events, [1] [2] [3] [4] [5] [6] [7] knowledge of the optimum achieved BP range in preventing CVD and all-cause mortality is important to help inform clinical practice and policy planning.
T he risks of cardiovascular diseases (CVD) and all-cause mortality in patients with diabetes mellitus (DM) are thought to be related to suboptimal blood pressure (BP) control over a period of time, but the achieved target for pharmacological BP lowering remains unclear. As one of the key goals of DM management is to minimize the risk of events, [1] [2] [3] [4] [5] [6] [7] knowledge of the optimum achieved BP range in preventing CVD and all-cause mortality is important to help inform clinical practice and policy planning.
Many international guidelines provide a systolic BP (SBP) target as one of the goals for diabetic management. However, there is currently no consensus on the optimal SBP target varying from 130 mm Hg to 140 mm Hg. [1] [2] [3] [4] [5] [6] [7] The discrepancy results across several randomized controlled trials (RCTs) showed that the benefits of intensive SBP control on CVD or mortality was still a matter of prolonged controversy. [8] [9] [10] Inconsistent associations between SBP and risk of CVD and mortality have been found in several epidemiological studies, with some suggesting a positive linear, J-shaped or U-shaped relationship. [11] [12] [13] [14] [15] [16] Because of the heterogeneity of diabetic populations, a few studies also advocated that the aggressive treatment may not be appropriate for all patients, and a rigid and uniform target should be replaced with a more flexible and patient-centered target for diabetic patients. 4 These conflicting evidences leave clinicians with a high level of uncertainty to the optimal SBP target. Furthermore, the global trend is toward shifting delivery of diabetic care away from hospitals to primary care, 17 and most of the results from previous studies under RCTs or hospital-based settings may not be fully transferable to the diabetic patient managed in real-world primary care setting. Understanding the relationship between SBP and the incidences of CVD and all-cause mortality among hypertensive and diabetic patients with different characteristics in primary care, the risk reduction that can be achieved through controlling SBP and the achieved treatment goals of SBP level in pharmacological therapy can assist clinicians in setting evidence-based SBP targets and recommendations for intervention.
The aim of this study was to investigate the association between SBP with the incidence of CVD events and Abstract-The current trend on diabetes mellitus management advocates replacing the paradigm from a uniform to an individualized patient-centered systolic blood pressure (SBP), but there is no consensus on the achieved treatment goals of SBP level. The study aimed at evaluating the association between SBP and the risk of cardiovascular diseases (CVD) and all-cause mortality for diabetic patients to identify patient-centered treatment targets. A retrospective study was conducted on 95 086 Chinese adult primary care patients with type 2 diabetes mellitus and hypertension. Using the average of the annual SBP records (updated SBP) over a median follow-up of 5.9 years, the risks of overall CVD, all-cause mortality, and their composite associated with SBP were evaluated using Cox proportional hazards regression. Subgroup analysis was performed on the incidence of CVD by stratifying patient's baseline characteristics. 
Methods

Study Design
This was a territory-wide retrospective cohort study that included all Chinese patients aged ≥18 years, who were clinically diagnosed with T2DM and hypertension and without prior history of CVD before baseline and received DM management in primary care. Clinical data were collected from the administrative database of the Hong Kong Hospital Authority (HA) for patients who had received primary care services from any of the 74 general outpatient clinics of the HA between January 1, 2009, and December 31, 2010. The HA is the governing body of all public-sector hospitals and primary care clinics in Hong Kong. Because of large subsidized public healthcare system managing in Hong Kong, the HA provides care for at least 90% of the diagnosed local diabetic patients. 18 The date of the first prescription of antihypertensive drugs between January 1, 2009, and December 31, 2010, was defined as baseline. Each patient was followed-up until the date of diagnosis of an outcome event, death, or last follow-up as of the censoring date of November 30, 2015, whichever occurred first.
Clinical diagnosis of T2DM and hypertension was identified using the International Classification of Primary Care-2 (ICPC-2) code of T90 and K86/K87, respectively. The primary outcomes of interest were incidence of composite of all-cause mortality and CVD, including coronary heart disease (CHD), stroke, and heart failure. The secondary outcomes were CVD, each subtype of CVD, and all-cause mortality. CHDs including ischemic heart disease, myocardial infarction, coronary death, and sudden death were identified by ICPC-2 of K74 to K76 Although there was no validation study performed to assess the accuracy and completeness of the coding, a previous study showed that only 1.5% and 5.5% of records were miscoded or lacked coding, respectively, for the diagnosis of DM using ICPC-2 in the clinical management system of HA. 19 Moreover, in routine clinical practice, clinicians in clinical and hospital settings provide ICPC-2 and International Classification of Diseases, Ninth Edition, Clinical Modification codes, respectively, for each episode of attendance. 20, 21 Another study also demonstrated reliability of the administrative database of HA to capture demographics and use of antidiabetic drugs with an almost perfect level of data completeness on demographics (100%) and drug prescription (99.98%). 20 Furthermore, because of heavily subsidized healthcare system in Hong Kong, patients with chronic diseases and serious complications, for example, myocardial infarction, were mostly treated in the HA public healthcare system. Therefore, the cohort in the present study should have captured nearly all CVD outcomes of DM patients who are managed in the HA primary care setting. In term of mortality data, the records were extracted from the Hong Kong Death Registry, which is a population-based government official registry covering all registered deaths for the residents of Hong Kong. These mortality data have been used widely in governmental departments; and thus should be highly reliable.
Consent of participants was not necessary as all data were anonymous and were extracted through the computerized administrative system of the HA. Ethics approval was received from all the region- 
Updated BP and Measurements
The guideline for obtaining and documenting SBP readings in diabetic patients during baseline and follow-up was standardized among all general outpatient clinics. 22 SBP was measured multiple times at each single visit, with an interval of at least 1 minute, after at least 5 minutes without any distractions in seated position, using a standardized semiautomated oscillometric device (UA-853, Tokyo, Japan; or Edan M3A, Shenzhen, China). If the difference between the 2 readings exceeded 5 mm Hg, an additional measurement was performed. The record of each SBP measurement was defined as the average of these readings.
The updated SBP value was defined as the average of all annual SBP measurements. For instance, if the follow-up period was 2 years, then the updated mean value was calculated by averaging the baseline, 1-year and 2-year SBP measurements. This approach has been widely used to investigate the association between clinical parameter and the incidences of morbidity and mortality. 12, 23, 24 The average number of SBP readings recorded was 6.0, and at least 93.0% had at least 3 SBP records until last follow-up among our subjects.
Baseline covariates consisted of patient's sociodemographics, clinical parameters, disease characteristics, and treatment modalities. Sociodemographics included sex, age, and smoking status. Clinical parameters included hemoglobin A1c (HbA1c), BMI, diastolic BP, lipid profile (low-density lipoprotein cholesterol and total cholesterol to high-density lipoprotein-cholesterol ratio), triglyceride, and estimated glomerular filtration rate. Disease characteristics included self-reported duration of DM. Comorbidity was measured using the Charlson comorbidity index. 25, 26 Treatment modalities composed of the usages of antihypertensive drug (eg, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, β-blocker, calcium channel blocker, diuretics, and others [hydralazine, methyldopa, and prazosin]), oral antidiabetic drugs, insulin, and lipid-lowering agents. All laboratory assays were performed in accredited laboratories by the College of American Pathologists, the Hong Kong Accreditation Service, or the National Association of Testing Authorities, Australia.
Data Analysis
Multiple imputation was used to handle missing data for baseline covariates (except SBP). 27 In this study, each missing value was imputed 5 times by the chained equation method. For each of the 5 imputed data sets, the same analysis was performed with the 5 sets of results combined based on Rubin rules. 28 All subjects were categorized as 1 of 10 groups according to the updated SBP value (<120 mm Hg, 120-124 mm Hg, 125-129 mm Hg, 130-134 mm Hg, 135-139 mm Hg, 140-144 mm Hg, 145-149 mm Hg, 150-154 mm Hg, 155-159 mm Hg, and ≥160 mm Hg). Descriptive statistics were shown after multiple imputation for each subgroup of SBP. The incidence rate was estimated by an exact 95% confidence interval based on a Poisson distribution. 29 The SBP groups associated with the incidence of CVD were examined using multivariable Cox proportional hazards regressions, adjusted by all baseline covariates. Moreover, the nonlinear association between updated SBP and CVD for each outcome was assessed by the restricted cubic splines with 3 knots in Cox models. 30 The proportional hazards assumption was checked by examining plots of the scaled Schoenfeld residuals against time for the covariates. Presence of multicollinearity was also checked by examining the variance inflation factor. Analysis of the data showed that all models fulfilled proportional hazards assumption and no multicollinearity existed. To eliminate the potential bias from the imbalanced number of patients in current groups, the main analyses were repeated by dividing the cohort into decile group of updated SBP levels. Four scenarios on the exclusion of patients either with follow-up period ≤1 year after baseline or with history of lung disease, cancer, or chronic kidney disease on or before baseline, and with complete data were subsequently performed as sensitivity analyses to avoid potential bias because of severe disease at baseline. , ≥5) , number of types of antihypertensive drugs used (1 kind, 2 kinds, ≥3 kinds), and usages of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, β-blocker, calcium channel blocker, and diuretic at baseline.
All significance tests were 2-tailed and those with a P value <0.05 were considered statistically significant. The statistical analysis was performed in Stata Version 13.0.
Results
There were a total of 106 101 Chinese patients with T2DM aged ≥18 years with valid SBP measurements and received DM care in one of the primary care clinics of HA between January 1, 2009, and December 31, 2010. A total of 95 086 diabetic patients were included in the data analysis after excluding 10 981 patients with CVD history and 34 patients without follow-up after baseline. Data completion rates for most baseline factors were >85%.
The baseline characteristics for overall cohort and each SBP group after multiple imputation are summarized in Table 1 . As a whole, 42.8% were male; mean age was 66.7 years (SD: 11.0 years); updated SBP was 137.6 mm Hg (SD: 10.7 mm Hg). The number and unadjusted incidence rates of the 4 outcome events for each SBP group are shown in Table 2 . During a median follow-up period of 51.5 to 81.5 months, the incidence rates of CVD were between 19.5 and 105.5 per 1000 person-years among SBP groups. Multivariable Cox proportional hazards regressions were also performed, and the corresponding hazard ratios for the marginal effects of SBP are shown and plotted in the Figure and Figure S1 in the online-only Data Supplement with and without restricted cubic spline. After adjusting for all baseline characteristics, the J-shaped associations between SBP level and incidence for each outcome were preserved. In terms of SBP, group 4 (130-134 mm Hg), the reference group, had the lowest risk of CVD and mortality and patients with SBP <125 mm Hg or ≥140 mm Hg had significantly higher risk. Repeated analysis by dividing the cohort into decile group of updated SBP levels in Tables S1 and S2 , and Figure S2 demonstrated similar J-shaped association between SBP level and the outcomes. Four different sensitivity analyses were performed by considering the exclusion of (1) patients with follow-up period ≤1 year after baseline; (2) patients with history of lung disease, cancer, or chronic kidney disease on or before baseline; (3) both (1) and (2); and (4) with complete data. The results obtained were almost identical to the main analysis of a J-shaped curvilinear relationship between SBP level and CVD incidence with an optimal SBP range between 130 to 134 mm Hg for each outcome. Similar J-shaped pattern ( Figure S3 ) was observed on the risk of CVD by stratifying sex, age group, duration of DM, smoking status, SBP, BMI, estimated glomerular filtration rate, Charlson index, and usages of different antihypertensive drugs at baseline.
Discussion
This population-based cohort study is the first to examine the effect of SBP on the risks of CVD and all-cause mortality among Chinese hypertensive patients with T2DM managed in primary care. A key finding from this study identified the optimal level of achieved SBP of 125 to 139 mm Hg for the lowest risk of having all-cause mortality and CVD event including CHD, stroke, and heart failure, which supports the SBP target of 140 mm Hg in several international guidances in diabetic management. The current findings also demonstrated a J-shaped curvilinear relationship between SBP and incidence of CVD and all-cause mortality among diabetic population, irrespective of patients' characteristics, and thus lower BP is not always better and may even be potentially hazardous. While the J-curve pattern was shifted slightly to the right in patients with age ≥65 years, similar results were obtained that patients with SBP <125 mm Hg or ≥140 mm Hg had an increased risk of CVD and mortality. Hence, the individualized SBP target may not be necessary in diabetic management.
Our findings were consistent with the results of previous clinical trials and observational studies which have also found a J-shape relationship between BP and cardiovascular outcomes. The Action to Control Cardiovascular Risk in Diabetes, Cochrane review, and 2 meta-analyses also concluded that lower BP targets (SBP<120 mm Hg for Action to Control Cardiovascular Risk in Diabetes; SBP<130 mm Hg for other) do not reduce macrovascular complications and mortality, but can increase the risk of adverse events attributed to hypertensive therapy. [8] [9] [10] 31 While Action to Control Cardiovascular Risk in Diabetes illustrated the advantage of the treatment SBP goal below 120 mm Hg on stroke in RCT, 31 a post hoc analysis from Action to Control Cardiovascular Risk in Diabetes showed that achieving SBP<120 mm Hg cannot attenuate the risk of all-cause mortality, overall CVD, myocardial infarction, and stroke compared with achieving SBP 120 to 140 mm Hg. 32 A cohort study conducted in the United States found similar results with the current study that SBP<110 mm Hg was associated with increased risks of CHD, stroke, and heart failure. [11] [12] [13] Two observational studies conducted in the United Kingdom also found an increased incidence of mortality at SBP<125 mm Hg. 15, 16 A meta-analysis also demonstrated that antihypertensive treatment evaluated the risk of mortality caused by CVD at SBP<140 mm Hg. 33 There is still no consensus on why low BP levels are associated with higher risks of CVD and all-cause mortality. 34, 35 Possible reason may be attributable to underperfusion, some unmeasured variables such as frailty, and undiagnosed heart failure. 15, 36 Conversely, the UKPDS (United Kingdom Prospective Diabetes Study) identified a positive linear relationship between SBP and macrovascular complications and mortality, concluding that diabetic patients with SBP<120 mm Hg had the lowest risk of events.
14 The SPRINT (Systolic Blood Pressure Intervention Trial) also reached the same conclusion with UKPDS among patients at high risk for CVD but without DM. 37 In comparing this current study's findings to earlier studies, our study had a much larger sample size of subjects with SBP<120 mm Hg and is better powered to examine the outcomes of patients with lower SBP. On the other hand, the unattended automated office BP measurements, which aims to minimize the white coat effect, was used in SPRINT, 37 and thus the BP values in SPRINT may underestimate conventional office BP measurements by ranging from 5 mm Hg to 16 mm Hg. 38 Several concern groups pointed out that caution should be taken when translating the SPRINT targets into the real-world clinical practices, [39] [40] [41] as same targets applied in routine practices may fall into the left side of the J-curve.
Of interest, the findings from the present study showed that the J-curve pattern was shifted slightly to the right in older patients but patients with SBP≥140 mm Hg had an increased risk of CVD and mortality, irrespective of patients' age. A few updated international guidelines advocated a looser treatment SBP for elderly patients. 1, 5 For example, the Eighth Joint National Committee Report and the International Diabetes Federation advocated treatment goal for SBP of <150 mm Hg for patients aged ≥60 and ≥80 years, respectively. 1, 5 Nevertheless, 2 landmark RCTs, Systolic Hypertension in Elderly Program for people aged ≥60 years and Hypertension in the Very Elderly Trial for people aged ≥80 years, showed the benefit of treating hypertension for SBP to around 140 mm Hg on health outcomes including mortality, stroke, and heart failure. 42, 43 A recent prospective cohort study conducted in the general population aged 65 to 94 years from Australia also provided evidence that there was a direct positive association between SBP and CVD throughout the SBP ranging from 145 to 170 mm Hg, even at 85 to 94 years. 44 Our results indicated that this increased risk for CVD event and mortality extends to patients with SBP>140 mm Hg regardless their age.
This study consisted of a large number of diabetic patients, and thus a greater number of events allowed a more precise estimate on the strength of association. A multiple repeated measurement for SBP, regression, and stratified analyses were able to evaluate the association between SBP and outcome events comprehensively. Clinical characteristics were closely captured by the HA's computerized administrative database allowing accurate access to relevant baseline covariates such as laboratory results, disease characteristics, and treatment modalities. Multiple imputations were used to replace the missing data to avoid biased results.
There were also several limitations to this study. First, our design was a retrospective cohort study which evaluates associations but not causation. To confirm the association between BP and CVD and all-cause mortality among Chinese diabetic patients, a more convincing study design like RCT would be required. Nonetheless, the common limitations of RCTs like UKPDS included high attrition rates, low number of incident events, short follow-up times, and strict subject's inclusion criteria that reduce the applicability to diabetic patients in clinical practices, with building evidence to support the value of observational studies in producing similar results to RCTs. [45] [46] [47] In addition, the probability of reverse causation was low in the current study as all our patients were without previous CVD at baseline, and the results were similar in sensitivity analysis after excluding patients with follow-up period ≤1 year or with history of lung disease, cancer, or chronic kidney disease. The current results were also adjusted with Charlson comorbidity index and the subgroup analysis by stratifying Charlson comorbidity index found similar results. Second, lifestyle interventions such as regular exercise and diet modification which may contribute to CVD risk were not taken into account in the analysis. However, the disease characteristics, such as duration of T2DM and the severity of chronic kidney disease, and some key clinical parameters like BMI, waist circumference, HbA1c, BP, and lipid, to a certain extent, reflecting the intensity of disease severity and lifestyle modification, have been considered. Third, this study highlighted the relationship between low BP level and the increased risks of CVD and all-cause mortality. However, this pattern of association between BP and outcomes excluded cluster effect across clinics and thus may differ in the general population and other Chinese diabetic populations from other regions. The relationship may be subject to temporal changes and modifications in unmeasured risk factors or interventions. Researchers should be cautious when adopting the study findings in other settings. Finally, All parameters are expressed in either percentage or mean±SD. ACEI indicates angiotensin-converting enzyme inhibitor; ACR, albumin/creatinine ratio; ARB, angiotensin receptor blocker; BMI, body mass index; CCB, calcium channel blocker; DBP, diastolic blood pressure; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; and TC, total cholesterol. *Significant difference (P<0.05) by ANOVA or χ 2 test, as appropriate.
the long-term effects on BP, CVD, and all-cause mortality are uncertain among Chinese diabetic patients. Further longitudinal studies with longer follow-up period are warranted to reappraise the association between low BP and incidence CVD events and mortality to confirm the reasons contributing to the excess mortality at lower BP. CHD indicates coronary heart disease; CI, confidence interval; CVD, cardiovascular disease; and SBP, systolic blood pressure. *Incidence rate (cases/1000 person-years) with 95% CI based on Poisson distribution. †Hazard ratios were adjusted age, gender, smoking status, body mass index, hemoglobin A1c, diastolic blood pressure, triglyceride, total cholesterol to high-density lipoprotein-cholesterol ratio, low-density lipoprotein cholesterol, estimated glomerular filtration rate, duration of diabetes mellitus, the usages of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, β-blocker, calcium channel blocker, diuretic, other antihypertensive drugs, oral-diabetic drugs, insulin and lipid-lowering agent, and Charlson index at baseline.
‡Significant difference (P<0.05) by multivariable Cox proportional hazards regression.
Perspectives
This large territory-wide naturalistic primary care study showed a J-shaped pattern between SBP and risks of allcause mortality and CVD events including CHD, stroke, and heart failure. The increased risk associated with low levels of SBP (<125 mm Hg) should make clinicians cautious against overtreatment of Chinese hypertensive T2DM patients without existing complications. The level of achieved SBP of 125 to 139 mm Hg in pharmacological therapy, irrespective of sex, age, smoking status, duration of DM, BMI, kidney function, severity of comorbidities, and treatment modalities, support the SBP treatment goal of <140 mm Hg, and the individualized SBP target may not be necessary in diabetic management.
Figure. Adjusted hazard ratios for incidence of (A) cardiovascular diseases, (B) coronary heart disease, (C) stroke, (D) heart failure, (E) all-cause mortality, and (F) composite of cardiovascular disease and mortality among all subjects by multivariable Cox proportional hazards regressions. Hazard ratios were adjusted by age, gender, smoking status, body mass index (BMI), hemoglobin A1c, diastolic blood pressure, triglyceride, total cholesterol to high-density lipoprotein-cholesterol ratio, low-density lipoprotein cholesterol, estimated glomerular filtration rate (eGFR), duration of diabetes mellitus (DM), the usages of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (ACEI/ARB), β-blocker, calcium channel blocker (CCB), diuretic, other antihypertensive drugs, oral-diabetic drugs, insulin and lipid-lowering agent, and Charlson index at baseline.
